心脏标志物的临床应用进展  

Clinical Application and Progress of Cardiac Markers

作　　者：代雷阳 钱净[1] 张鸿伟[1] 杨丽琼[1] 

机构地区：[1]昆明医科大学附属甘美医院暨昆明市第一人民医院检验科,昆明650000

出　　处：《医学综述》2017年第12期2323-2327,共5页Medical Recapitulate

摘　　要：心脏标志物在心脏或心血管异常的情况下由心脏大量释放,因其敏感性和特异性都相对较高,提高了对微小心肌损伤的检出成功率,对常见心血管疾病诊疗提供了较好的实验室证据。心肌标志物从传统的心肌酸激酶同工酶,进展到心肌肌钙蛋白和三联心肌标志物,以及目前临床应用中的新型生物标志物如心脏型脂肪酸结合蛋白、N端钠尿肽前体等,它们在心肌损伤、急性冠状动脉综合征、心力衰竭等疾病的诊断、治疗和预后判断等方面具有重要意义。Cardiac markers（ CM）,are released by heart in the case of the heart or cardiovascular anomalies. Due to the relatively high sensitivity and specificity,CM improves the successful rate of detection of minor damage,and provides better laboratory evidences of common cardiovascular diseases diagnosis. From traditional CM of creatine kinase-MB and cardiac troponin to three terms together to human heart fatty acid binding protein,and N-terminal pronatriuretic peptide which are novel biomarkers,they all have important meanings in the diagnosis,treatment and prognosis judgment of myocardial injury,acute coronary syndrome,heart failure and other diseases.

关 键 词：心脏标志物 心血管疾病 临床意义 

分 类 号：R446.1[医药卫生—诊断学]